pLKO-RB1-shRNA63 Citations (8)
Originally described in: Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James CD, Waldman T Cancer Res. 2010 Apr 15. 70(8):3228-38. PubMed Journal
Articles Citing pLKO-RB1-shRNA63
| Articles |
|---|
Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J.
Clin Cancer Res. 2013 Apr 1;19(7):1748-59. doi: 10.1158/1078-0432.CCR-12-3066. Epub 2013 Feb 12.
PubMed
Associated Plasmids |
| Rb suppresses collective invasion, circulation and metastasis of breast cancer cells in CD44-dependent manner. Kim KJ, Godarova A, Seedle K, Kim MH, Ince TA, Wells SI, Driscoll JJ, Godar S. PLoS One. 2013 Dec 4;8(12):e80590. doi: 10.1371/journal.pone.0080590. eCollection 2013. PubMed |
| Ras regulates Rb via NORE1A. Barnoud T, Donninger H, Clark GJ. J Biol Chem. 2015 Dec 16. pii: jbc.M115.697557. PubMed |
| L1 drives IFN in senescent cells and promotes age-associated inflammation. De Cecco M, Ito T, Petrashen AP, Elias AE, Skvir NJ, Criscione SW, Caligiana A, Brocculi G, Adney EM, Boeke JD, Le O, Beausejour C, Ambati J, Ambati K, Simon M, Seluanov A, Gorbunova V, Slagboom PE, Helfand SL, Neretti N, Sedivy JM. Nature. 2019 Feb;566(7742):73-78. doi: 10.1038/s41586-018-0784-9. Epub 2019 Feb 6. PubMed |
| Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Qie S, Yoshida A, Parnham S, Oleinik N, Beeson GC, Beeson CC, Ogretmen B, Bass AJ, Wong KK, Rustgi AK, Diehl JA. Nat Commun. 2019 Mar 21;10(1):1296. doi: 10.1038/s41467-019-09179-w. PubMed |
| GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, Chen W, Nie Y, Zhang LX, Vellanki RN, Zhou S, Prinos P, Wouters BG, Dirks PB, Done SJ, Park M, Cescon DW, Haibe-Kains B, Lupien M, Arrowsmith CH. Nat Commun. 2020 Aug 21;11(1):4205. doi: 10.1038/s41467-020-18020-8. PubMed |
| Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer. Klein FG, Granier C, Zhao Y, Pan Q, Tong Z, Gschwend JE, Holm PS, Nawroth R. J Pers Med. 2021 Apr 24;11(5). pii: jpm11050340. doi: 10.3390/jpm11050340. PubMed |
| An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoglanoglu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, Talal A, Stelloo S, van der Poel H, Bergman AM, Ahmed M, Fazli L, Huang H, Tilley W, Goodrich D, Feng FY, Gleave M, He HH, Hach F, Zwart W, Beltran H, Selth L, Zoubeidi A. Nat Cell Biol. 2021 Sep;23(9):1023-1034. doi: 10.1038/s41556-021-00743-5. Epub 2021 Sep 6. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.